Emma Walmsley, GSK CEO

GSK touts record Shin­grix sales as Zan­tac cas­es go to tri­al

Months af­ter GSK changed its name from Glax­o­SmithK­line and spun off its con­sumer health di­vi­sion in­to the stand­alone Ha­le­on, the Big Phar­ma is re­port­ing bet­ter-than-ex­pect­ed sales — with both op­por­tu­ni­ties and chal­lenges ahead.

CEO Em­ma Walm­s­ley tout­ed record sales of shin­gles vac­cine Shin­grix on the earn­ings call Wednes­day, not­ing that the vac­cine record­ed £760 mil­lion in sales for the quar­ter — over $800 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.